Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy.

Abstract

BACKGROUND:

Gastrointestinal involvement in Gaucher disease is very rare, and appears to be unresponsive to enzyme replacement therapy (ERT).

CASE PRESENTATION:

Here, we describe identical twin, splenectomized, non-neuronopathic Gaucher patients on long-term ERT for 9 years, who complained of epigastric discomfort due to Gaucher cell infiltration of the gastroduodenal mucosa. Rare compound heterozygous mutations (p.Arg48Trp and p.Arg257Gln) of the GBA gene were found in both. Improvement in the gastroduodenal infiltration and reduced chitotriosidase levels were observed in one who switched to eliglustat tartrate for 1 year, whereas the other one who maintained ERT showed no improvement of chitotriosidase level and persistent duodenal lesions.

CONCLUSION:

This shows that eliglustat might be an effective treatment for Gaucher disease patients having lesions resistant to ERT.

• Authors: Yoo-Mi Kim, Dong Hoon Shin, Su Bum Park, Chong Kun Cheon, Han-Wook Yoo
• Journal: BMC medical genetics (BMC Med Genet) Vol. 18 Issue 1 Pg. 55 (05 15 2017) ISSN: 1471-2350 [Electronic] England
• PMID: 28506293 (Publication Type: Case Reports, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Enzyme Inhibitors
• Pyrrolidines
• eliglustat
• Hexosaminidases
• chitotriosidase
• beta-Glucosidase

Topics

• Adult
• Child
• Duodenum (pathology)
• Enzyme Inhibitors (therapeutic use)
• Enzyme Replacement Therapy (methods)
• Gaucher Disease (drug therapy, genetics)
• Hexosaminidases (metabolism)
• Humans
• Infant
• Male
• Pyrrolidines (therapeutic use)
• Treatment Outcome
• Twins, Monozygotic
• beta-Glucosidase (genetics)